Select Page

Edmonton, May 28-30, 2023

Due to the numerous requests from LPs. Micro and Craft growers along with some of the largest cannabis retail stores in the nation, Grow Up has decided to bring our award winning show to Alberta. We will be hosting our 7th Conference and Expo at the Edmonton Convention Centre in beautiful downtown Edmonton.

Psychedelic Drug Developers to Carry Out Clinical Trials in UK

Media Partners, Psychedelic News Wire

This post is presented by our media partner Psychedelic News Wire
View the original article here.

Some psychedelic medicine developers in the United States and Canada have entered into an agreement with Clerkenwell Health in order to carry out trials on their drugs for various mental health indications in the United Kingdom. Clerkenwell Health is a clinical research organization that conducts trials for therapies for a range of mental health illnesses in London.

The drug developers hope to treat mental health conditions such as major depressive disorder, social anxiety, nicotine addiction and autism spectrum disorder as well as adjustment disorder for patients with diagnoses of terminal illnesses, including cancer.

Data from trials conducted in the United Kingdom are globally accepted. This is why many companies carry out phase I and phase II clinical trials there before seeking out larger markets.

The regulatory pathway and fast-track drug approval process in the United Kingdom allows companies to speed up their applications. Since the combined regulatory review process was implemented a few years ago, approval periods have also gotten shorter with ethics applications for fast-tracking that allow approvals in 60 days also being debuted in August this year.

The developers in question include Psyence, Mydecine, PharmAla Biotech and Mindset Pharma; these companies all hope to benefit from the UK’s fast-paced drug regulatory process.

Psyence is a biotechnology company that recently received approval from the Medicines and Healthcare Products Regulatory Agency to conduct trials on its psilocybin-assisted therapy to support patients with terminal cancer through end-of-life care. The company, which is based in Toronto, has a growing facility for hallucinogenic mushrooms in South Africa. Psycence exports these mushrooms to Canada and Portugal for research purposes.

Mydecine is focused on the development of a psilocybin-derived compound for the treatment of tobacco addiction. The company, which is based in Colorado, provided this drug to Johns Hopkins University after it was awarded a grant from the NIH, a federal health agency, for its study on smoking cessation in the United States.

Mindset Pharma is focused on the development of various products, including a compound similar to psilocybin for the treatment of major depressive disorder. Clerkenwell plans to assist Mindset with scientific advice and regulatory submission. Mindset Pharma CEO, James Lanthier, stated that the company was excited to progress its research into how second-generation psychedelic drugs could be utilized in the treatment of psychiatric and neurological disorders.

PharmAla has developed an MDMA-derived drug for the treatment of autism spectrum disorder. The company, which is the only producer of pharmaceutical-grade MDMA within North America, is based in Toronto.

Clerkenwell plans to support PharmaAla via the process of approving its trial by both U.S. and British regulators — the U.S. Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA), respectively.

With enterprises such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) making progress in studies within the United States, success for the companies conducting trials in the UK would bring more psychedelic-based options to patients in need not just in North America but around the world.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

This post was originally published by our media partner here.